-
Product Insights
Hyperthyroidism: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Hyperthyroidism - Global Clinical Trials Review, 2026" provides an overview of Hyperthyroidism Clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperthyroidism. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Crohn's Disease (Regional Enteritis): Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Crohn's Disease (Regional Enteritis) - Global Clinical Trials Review, 2026" provides an overview of Crohn's Disease (Regional Enteritis) Clinical trials scenario. This report provides top line data relating to the clinical trials on Crohn's Disease (Regional Enteritis). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy): Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Global Clinical Trials Review, 2026" provides an overview of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Clinical trials scenario. This report provides top line data relating to the clinical trials on Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7...
-
Product Insights
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia): Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Global Clinical Trials Review, 2026" provides an overview of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Clinical trials scenario. This report provides top line data relating to the clinical trials on Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Dermatomyositis: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Dermatomyositis - Global Clinical Trials Review, 2026" provides an overview of Dermatomyositis Clinical trials scenario. This report provides top line data relating to the clinical trials on Dermatomyositis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
Systemic Lupus Erythematosus and Lupus Nephritis Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
This report covers the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends. Key topics covered include a strategic competitive assessment of current and future drugs, unmet needs, KOL insights, and implications for the Systemic Lupus Erythematosus and Lupus Nephritis market. The base year of the sales forecast model is 2024, and the forecast period...
-
Sector Analysis
Global Pain Therapeutics Market and Modality Trends
The current pain market is dominated by NSAIDs and opioids.​ There are currently 391 innovator drugs marketed for pain indications globally.​ The pain market is highly genericized, with generics accounting for 98% of all marketed pain drugs globally. The most significant R&D trend in pain is the emergence of voltage-gated sodium channel (NaV) inhibitors, in particular NaV1.8 and NaV1.7, as a validated therapeutic modality.​ Compared with the marketed landscape, there is more diversity in the pain pipeline in terms of...
-
Sector Analysis
Aspergillosis: Market View, Current and Future Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Aspergillosis Therapeutics. • In 2024 and 2029, India is anticipated to have the highest number of diagnosed incident cases of aspergillosis, representing a large portion of global cases. • Currently, the aspergillosis market is saturated with generic drugs. Triazoles, polyenes, and echinocandins are primarily used to manage aspergillosis. • The aspergillosis pipeline holds 37 molecules, with no assets in the pre-registration stage, four assets in Phase...
-
Thematic Analysis
Pharma M&A Deals 2025 - Top Themes: Strategic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in 2025 in the pharma Sector.
-
Sector Analysis
Myopia and Pediatric Myopia Progression: Market View, Current and Future Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Myopia and Pediatric Myopia Progression Therapeutics. • In 2024 and 2029, China is anticipated to have the highest number of total prevalent adult cases of myopia, representing a large portion of global cases. • Currently, myopia and pediatric myopia progression have no FDA-approved drug for treatment. Atropine sulfate is the primary established treatment prescribed for significantly slowing axial eye growth and preventing myopia from getting worse....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.